The present study investigated the effect of cytochrome P450 2C9 (CYP2C9) genetic polymorphism on the biotransformation of valproic acid (VPA) to its hepatotoxic metabolite, 4-ene-VPA, and compared that to the formation of the inactive 4-OH-VPA and 5-OH-VPA. cDNA-expressed CYP2C9*2 and CYP2C9*3 variants were less efficient than the CYP2C9*1 wild type in catalyzing the formation of these metabolites, as assessed by the ratio of Vmax and apparent Km (in vitro intrinsic clearance). The reduced efficiency by CYP2C9*2 was due to a reduced Vmax, whereas, in the case of CYP2C9*3, it was the result of increased apparent Km. The formation rates of 4-ene-VPA, 4-OH-VPA, and 5-OH-VPA in human liver microsomes were reduced by 29, 28, and 31%, respectively, in samples with one mutated CYP2C9 allele, and by 61, 73, and 58%, respectively, in samples with two mutated CYP2C9 alleles. Overall, the homozygote and heterozygote CYP2C9*2 and CYP2C9*3 genotypes may compromise hepatic VPA biotransformation.
INTRODUCTION
Valproic acid (VPA) is used frequently in the management of epilepsy. 1 Other clinical indications of this drug include bipolar disorder, neuropathic pain, and prophylactic treatment of migraine headache. The therapeutic use of VPA may lead to a rare but fatal hepatotoxicity that is characterized by steatosis with or without necrosis of the liver. 2 Risk factors associated with VPA-induced hepatotoxicity include an age of less than 2 years, multiple anticonvulsant drug therapy, and concurrent medical disorders. 3 The mechanism of VPA-induced hepatotoxicity is not known, but it has been postulated that 4-ene-VPA, which is an oxidative metabolite of VPA, may be biotransformed to an electrophilic diene that inhibits mitochondrial b-oxidation enzymes and depletes cellular gluthathione. 4 Cytochrome P450 2C9 (CYP2C9) is expressed predominantly in the human liver, although it has also been detected in various extrahepatic tissues. 5 This is an important drug-metabolizing enzyme because it catalyzes the biotransformation of many clinically useful drugs, including phenytoin, 6 tolbutamide, 6, 7 warfarin, 8 the alkylating anticancer prodrugs cyclophosphamide and ifosfamide, 9 and nonsteroidal anti-inflammatory drugs such as naproxen 10 and ibuprofen. 11 To date, several allelic variants of CYP2C9 have been identified.
These are CYP2C9*1 (Arg144KIle359KAsp360), CYP2C9*2 (Cys144KIle359KAsp360), CYP2C9*3 (Arg144KLeu359-KAsp360), CYP2C9*4 (Arg144KThr359KAsp360), and CYP2C9*5 (Arg144KIle359KGlu360). Recently, a null allele, designated as CYP2C9*6, was identified in a patient who developed toxicity to phenytoin. 14 The CYP2C9 singlenucleotide polymorphisms result in a reduced intrinsic drug clearance, 12, 15 but the magnitude of the effect, which ranges from 3-to 34-fold, appears to be drug-dependent. 16 Previous rodent studies have established a role for cytochrome P450 enzymes in the hepatic biotransformation of VPA to form 4-ene-VPA (Figure 1 ), which is a hepatotoxic metabolite. 4 In a study with human liver microsomes and cDNA-expressed cytochrome P450 enzymes, it was concluded that CYP2C9 catalyzes the metabolic activation of VPA to form 4-ene-VPA. 17 However, it is not known whether CYP2C9 genetic polymorphism influences the oxidative biotransformation of VPA. Therefore, the objectives of the present study were: (1) to compare the enzyme kinetics of cDNA-expressed CYP2C9*1, CYP2C9*2, and CYP2C9*3 in the metabolism of VPA to form 4-ene-VPA, and the various hydroxy-VPA metabolites ( Figure 1) ; (2) investigate the effect of the CYP2C9*1, CYP2C9*2, and CYP2C9*3 homozygote and heterozygote genotypes on VPA metabolism in a panel of individual human liver microsomes.
RESULTS

GC/MS Analysis of VPA Metabolites
The GC/MS ion chromatograms of 4-ene-VPA formed by cDNA-expressed human CYP2C9*1 and human liver microsomes are shown in Figure 2a and b, respectively. CYP2C9*1 also catalyzed the formation of 4-OH-VPA (two isomers) and 5-OH-VPA (Figure 2c ), whereas human liver microsomes catalyzed the formation of 4-OH-VPA (two isomers), 5-OH-VPA, and 3-OH-VPA (Figure 2d ). Authentic standards for the individual isomers of 4-OH-VPA were not available for the construction of standard curves. However, no quantitative differences were obtained in the amount of each isomers formed enzymatically by the CYP enzymes under our experimental conditions. Therefore, in the present study, the data for 4-OH-VPA represent the sum of the two individual isomers. The standard curves for 4-ene-VPA, 4-OH-VPA, 5-OH-VPA, and 3-OH-VPA were linear over the range of 1-500 ng/ml. At a concentration of 1 ng/ml, the intraday and interday variabilities for each of these assays were 9 and 12%, respectively.
Comparison of VPA Metabolism Catalyzed by CYP2C9 Allelic Variants
To compare the catalytic activity of CYP2C9*1, CYP2C9*2, and CYP2C9*3 with respect to VPA metabolism, enzymatic incubations were conducted with recombinant enzymes and at a substrate concentration (1 mM) that approximates the therapeutic plasma VPA levels in patients (0.4-0.7 mM). 1 Each of the three CYP2C9 enzymes was catalytically active in the in vitro metabolism of VPA to form 4-ene-VPA, 4-OH-VPA and 5-OH-VPA, but not 3-OH-VPA. When compared to CYP2C9*1, CYP2C9*2 was 48, 44, and 44% less active in the metabolic formation of 4-ene-VPA (Figure 3a ), 4-OH-VPA (Figure 3b) , and 5-OH-VPA (Figure 3c ), respectively. A greater decrease in enzyme activity was obtained with CYP2C9*3, which was 85, 83, and 88% less active than CYP2C9*1 in the formation of 4-ene-VPA (Figure 3a ), 4-OH-VPA (Figure 3b) , and 5-OH-VPA (Figure 3c) , and 5-OH-VPA (44%), whereas there was no significant difference in the apparent Km between these two CYP2C9 forms ( Table 1) . As a result, CYP2C9*2 was less efficient than CYP2C9*1 in metabolizing VPA to form these three metabolites, as assessed by the in vitro intrinsic clearance (ratio of Vmax/ apparent Km). By comparison, CYP2C9*3 was also less efficient than CYP2C9*1 in the metabolic formation of 4-ene-VPA, 4-OH-VPA, and 5-OH-VPA. However, in this case, the reduced in vitro intrinsic clearance was the result of an increase in the apparent Km and not due to a change in the Vmax. The apparent Km values were 2.6-, 3.3-, and five-fold greater for the metabolic formation of 4-ene-VPA, 4-OH-VPA, and 5-OH-VPA, respectively, by CYP2C9*3 when compared to CYP2C9*1.
Influence of CYP2C9 Genotype on VPA Metabolism
To determine the effect of CYP2C9 genetic polymorphism on VPA metabolism, we compared the rate of the metabolic conversion of VPA to 4-ene-VPA, 4-OH-VPA, and 5-OH-VPA in a panel of 39 individual human liver microsome samples of known CYP2C9 genotype. The formation rates of 4-ene-VPA (Figure 4a ), 4-OH-VPA (Figure 4b ), and 5-OH-VPA ( Figure 4c ) in human liver microsomes were not significantly different between the CYP2C9*1/*1, CYP2C9*1/*2, CYP2C9*1/*3, CYP2C9*2/*2, CYP2C9*2/*3, and CYP2C9*3/ *3 genotypes. However, the formation rates of the 4-ene-VPA, 4-OH-VPA, and 5-OH-VPA metabolites in the one CYP2C9*3/*3 sample were 62, 30, and 62% less than the mean formation rates of these metabolites in the CYP2C9*1/*1 group (N¼12 individual samples).
Further analysis was performed on the data stratified according to the number of mutated CYP2C9 alleles. As shown in Figure 5a , the rate of 4-ene-VPA formation was decreased by 29 and 61% in the samples with one and two mutated CYP2C9 alleles, respectively, when compared to the homozygote wild-type CYP2C9*1/*1 (P¼0.09). By compar- ison, there was also a trend toward a reduction in the rate of 4-OH-VPA formation (Figure 5b ) in the samples with one (28% decrease) and two (37% decrease) CYP2C9 mutated alleles (P¼0.24). The rate of 5-OH-VPA formation ( Figure 5c ) was reduced by 33% in the samples with one mutated allele and by 58% in the samples with two mutated alleles (P¼0.09).
DISCUSSION
The present study is the first to report the effect of CYP2C9 genetic polymorphism on the metabolic activation of VPA to form the hepatotoxic 4-ene-VPA and the inactive 4-OH-VPA and 5-OH-VPA metabolites in a panel of individual human liver microsomes. Specifically, we focused on the roles of CYP2C9*1, CYP2C9*2, and CYP2C9*3. The CYP2C9*2 variant differs from the wild-type CYP2C9*1 by a C 430 -T substitution in exon 3. 15 This alteration results in the replacement of the amino-acid arginine with cysteine at position 144. 18 The allelic frequency of CYP2C9*2 has been reported to be 8-19% in Caucasians, 1-4% in AfricanAmericans and Canadian Native Indians, and this allele has not been detected in Chinese or Japanese subjects. 12 In the present study, CYP2C9*2 was shown to be less efficient than CYP2C9*1 in metabolizing VPA. However, this was not due to differences in the apparent Km, but was the result of a reduced Vmax in the formation of 4-ene-VPA, 4-OH-VPA, and 5-OH-VPA by CYP2C9*2 when compared with CYP2C9*1. Similar enzyme kinetic effects have been reported for the in vitro metabolism of celecoxib in a recent study that also used recombinant CYP2C9*2 synthesized in baculovirus-infected insect cells cotransfected with NADPHcytochrome P450 reductase. 19 These findings are consistent with the proposal that amino acid 144 is not located in any of the putative substrate recognition sites for human CYP2C enzymes. 20 Consequently, the impact of CYP2C9*2 on catalytic activity is independent of substrate recognition. The reduced Vmax in VPA metabolism by this CYP2C9 variant is consistent with the idea that the Arg 144 -Cys substitution compromises the interaction between the CYP enzyme and NADPH-cytochrome P450 reductase. 21 The CYP2C9*3 variant differs from the wild-type CYP2C9*1 by an A 1075 -C substitution in exon 7. 15 This alteration results in the replacement of the amino acid isoleucine with leucine at position 359. 18 The allelic frequency of CYP2C9*3 has been reported to be 6-10% in Caucasians and Canadian Native Indians, 1.7-5% in Asians, and 0.5-1.5% in African-Americans. 12 In the present study, CYP2C9*3 was also found to be less efficient than CYP2C9*1 in the metabolic formation of 4-ene-VPA, 4-OH-VPA, and 5-OH-VPA, but this was the result of an increase in the apparent Km and not due to a change in the Vmax. This finding is consistent with the proposal that amino acid 359 in CYP2C9 resides in a putative substrate recognition site 20 and therefore plays a role in the affinity for the substrate. In a recent study, 16 it was shown that CYP2C9*3, when compared with CYP2C9*1, reduced the in vitro intrinsic clearance, but this was the result of an increase in the apparent Km (tolbutamide hydroxylation and diclofenac 4 0 -hydroxylation), a reduced Vmax (piroxicam 5 0 -hydroxylation), or both an increase in the apparent Km and a decrease in Vmax (phenytoin 4 0 -hydroxylation, tenoxicam 5 0 -hydroxylation, mefenamic acid 3 0 -hydroxylation, and S-warfarin 7-hydroxylation). The magnitude of the reduction in the in vitro intrinsic clearance by CYP2C9*3 ranges from 71% (diclofenac 4 0 -hydroxylation) to 97% (piroxicam 5 0 -hydroxylation). By comparison, CYP2C9*3 decreased the in vitro intrinsic clearance of 4-ene-VPA, 4-OH-VPA, and 5-OH-VPA by 69, 60, and 83%, respectively. 
CYP2C9 genotype and valproic acid metabolism
PC Ho et al
The CYP2C9*2 and CYP2C9*3 alleles did not appear to have influenced the regioselectivity of VPA metabolism, as assessed by the relative in vitro intrinsic clearances of the 4-ene-VPA, 4-OH-VPA, and 5-OH-VPA metabolites, which were 1 : 10 : 11 for CYP2C9*1, 1 : 11 : 12 for CYP2C9*2, and 1 : 13 : 6 for CYP2C9*3. By comparison, the ratio of the formation rates of 4-ene-VPA, 4-OH-VPA, and 5-OH-VPA was 1 : 18 : 9, as shown in a study with human liver microsomes. 17 Interestingly, a clinical pharmacokinetic study reported that the ratio of the area under the plasma concentration-time curve (AUC) for 4-ene-VPA, 4-OH-VPA, and 5-OH-VPA was 1 : 23 : 19.
Various case reports have suggested that the biotransformation of drugs such as S-warfarin 22, 23 and phenytoin 24, 25 are severely compromised in individuals who are homozygous for CYP2C9*3. The frequency of the homozygous CYP2C9*3 genotype is relatively small (approximately 1-2%) in Caucasians and this genotype has not been detected in other populations (eg Ethiopians). 26 A similar frequency of the homozygous CYP2C9*2 genotype has also been reported. 26, 27 In contrast, the heterozygote CYP2C9*2 and CYP2C9*3 genotypes are more common, with a prevalence of up to 19% in Caucasians. [26] [27] [28] Relatively little is known about the functional consequences of these heterozygote Figure 4 were stratified according to the number of mutated CYP2C9 alleles; none (CYP2C9*1/*1; N¼12), one (CYP2C9*1/*2 and CYP2C9*1/*3; N¼18), or two (CYP2C9*2/*2, CYP2C9*2/*3, and CYP2C9*3/*3; N¼9). Results are expressed as mean7SEM.
genotypes and the effects do not appear to be predictable. For example, the clearance of S-warfarin is decreased by 66% in CYP2C9*3 heterozygotes, 23 but this genotype has no effect on the biotransformation of other CYP2C9 drug substrates such as diclofenac [29] [30] [31] [32] and sulfamethoxazole. 33 In the present study, the formation rates of the 4-ene, 4-OH-, and 5-OH-VPA metabolite (at 1 mM substrate concentration) in human liver microsomes with the CYP2C9*1/*2, CYP2C9*1/*3, CYP2C9*2/*2, or CYP2C9*2/*3 genotype were not significantly different from those in the CYP2C9*1/*1 group. An explanation for this finding is the small number of samples analyzed, particularly in the CYP2C9*2/*2 and CYP2C9*2/*3 groups. When the data were stratified according to the number of mutated CYP2C9 alleles, there was a trend toward a reduction in VPA metabolism in the CYP2C9*2 and CYP2C9*3 homozygotes and the CYP2C9*2/*3 heterozygotes. Another explanation is that any reduction in the inherent capacity to metabolize VPA in human liver microsomes by CYP2C9*2 and CYP2C9*3 was mitigated by the activity of other VPA-metabolizing cytochrome P450 enzymes such as CYP2A6 17 and perhaps CYP2B6. 34 Studies are in progress to determine the contribution of individual cytochrome P450 enzymes to VPA metabolism in human liver microsomes.
Among the clinically useful anticonvulsants (ie phenytoin, VPA, carbamazepine, and phenobarbital) that undergo cytochrome P450-catalyzed biotransformation, the experimental evidence indicates that phenytoin 35 and VPA 17 are substrates for CYP2C9. Furthermore, pharmacogenetic studies have shown that the CYP2C9*2 and CYP2C9*3 alleles appear to compromise the elimination of phenytoin in humans. 15 By comparison, the in vivo significance of CYP2C9 in the oxidative biotransformation of VPA remains to be determined, but the results from the present in vitro study provide an impetus for future investigations to examine the effect of the homozygote and heterozygote CYP2C9*2 and CYP2C9*3 genotypes on the in vivo disposition of VPA in human subjects.
In summary, the novel findings from the present study are: (1) CYP2C9 catalyzed not only the formation of 4-ene-VPA, but also 4-OH-VPA and 5-OH-VPA; however, it was more efficient as a catalyst of 4-ene-VPA formation than of 4-OH-VPA or 5-OH-VPA formation; (2) the allelic variant CYP2C9*2 was less efficient than the CYP2C9*1 wild-type in metabolizing VPA, and this was the result of a reduced Vmax; (3) the allelic variant CYP2C9*3 was also less efficient than CYP2C9*1 in metabolizing VPA, but this was due to an increase in the apparent Km; and (4) there was a trend toward a reduction in the oxidative biotransformation of VPA in liver microsomes from CYP2C9*2 and CYP2C9*3 homozygotes and CYP2C9*2/*3 heterozygotes.
MATERIALS AND METHODS
Chemicals VPA (sodium salt) was purchased from Sigma Chemical Co. (St Louis, MO, USA). NADPH was bought from Roche Diagnostic Co. (Indianapolis, IN, USA) . N,N 0 -diisopropy- cDNA-Expressed Human CYP2C9 Enzymes and Human Liver Microsomes Microsomes isolated from baculovirus-infected insect cells coexpressing NADPH-cytochrome P450 reductase and CYP2C9*1, CYP2C9*2, or CYP2C9*3, control insect cell microsomes, and individual human liver microsomes with known CYP2C9 genotype were purchased from GENTEST Corp. (Woburn, MA, USA). Individual human liver microsome samples were also obtained from a tissue bank, as detailed elsewhere 37 and the CYP2C9 genotyping of these samples was determined as described previously. 38 The distribution of the CYP2C9 genotypes in our panel of 39 individual human liver microsome samples is listed in Table 2 .
Microsomal VPA Metabolism Assay Each standard 200 ml incubation mixture, containing 100 mM Tris (pH 7.4), 3 mM magnesium chloride, 1 mM VPA, cDNA-expressed CYP2C9 enzyme (40 pmol) or human liver microsomes (120 pmol total cytochrome P450), was preincubated at 371C for 2 min in a shaking water bath. The reaction was initiated by the addition of 1 mM NADPH. After incubating the reaction mixture at 371C for 30 min, the reaction was terminated by the addition of ice-cold 0.1 M phosphoric acid (75 ml). The mixture was vortexed and stored at À201C until metabolite analysis by GC/MS. Control incubations contained microsomes isolated from insect cells not transfected with NADPH-cytochrome P450 reductase cDNA or CYP2C9 cDNA. Preliminary experiments indicated that the VPA metabolism assay was linear with respect to incubation time and amount of enzyme. Calibration curves were generated with eight different 
Sample Extraction and Derivatization
The assay for VPA metabolites was modified from the method of Anari et al. 34 Microsomal incubation samples and 25 ml of an internal standard mixture containing 2 mg/ml of each deuterated metabolite standard were added to borosilicate glass screw-top culture tubes. Each sample was acidified to pH 3.5 and made up to 1 ml with 1 M KH 2 PO 4 buffer (pH 3.5). Ethyl acetate (6 ml) was added to each sample and extraction was performed by gentle rotation of the phases for 30 min prior to centrifugation (1600 g for 10 min at room temperature). The organic layer was transferred to another borosilicate glass screw-top test tube, dried over anhydrous sodium sulfate, vortex mixed, and centrifuged at 1600 g (10 min at room temperature). The organic layer was transferred to another set of screw-top test tubes and the ethyl acetate was evaporated to a volume of 100-200 ml under a gentle stream of nitrogen (301C, 0.5 p.s.i) using a Zymark Turbo Vap s LV evaporator (Zymark, Hopkinton, MA, USA). N,N 0 -Diisopropylethylamine (30 ml) and PFBBr (10 ml) were added to the sample, and the mixture was vortex-mixed and heated at 401C for 60 min for the pentafluorobenzyl ester derivatization of the carboxylic acid groups. The mixture was cooled at room temperature for the second derivatization step. Dimethylformamide (20 ml) and 40 ml of a mixture of 2% tert-butyldimethylsilyl chloride in MTBSTFA were added to the sample mixture and heated at 601C for 2 h for the tert-butyldimethylsilylation of hydroxyl groups. The derivatized sample was cleaned up to remove nonvolatiles by drying it down to a residue under a stream of nitrogen and reconstituting it in 75 ml of n-hexane (GC grade) by vortex mixing. The mixture was centrifuged (1600 g for 10 min), the hexane layer was transferred to an autosample vial, and 1 ml was injected onto the column for GC/MS analysis.
GC/MS Instrumentation
An HP6890 gas chromatograph (GC) interfaced to an HP5973 mass selective detector (Hewlett-Packard, Avondale, PA, USA) was used for the analysis of VPA metabolites. Samples were injected by an HP7683 autosampler. The mass spectrometric data acquisition and handling software HP Enhanced Chemstation Software G1701BA (V. B.01.00) was used to control the operation of all instruments. The separation of VPA metabolites was carried out on a fusedsilica capillary GC column (60 m Â 0.25 mm ID, 0.25 mm film thickness) coated with the nonpolar stationary phase SolGel-1mst (SGE Inc., Austin, TX, USA). A guard column (5 m Â 0.25 mm ID) (Phenomenex, Torrance, CA, USA) was connected to the analytical column by a fused-silica union. The carrier gas was helium and the septum purge flow rate was 20 ml/min for 2 min. Samples were injected in splitless mode at an injector temperature of 2501C, and cold trapped on the column at 401C for 0.5 min. The nominal initial pressure was 17.97 p.s.i. at a constant flow rate of 0.5 ml/ min. The column oven temperature program was set as follows: 751C/min to 1401C, then 11C/min to 1601C, followed by 101C/min to 2701C, and held at 2701C for 5 min. The temperatures of the ion source and the GC/MS interface were 200 and 2701C, respectively. The mass spectrometer was operated in negative-ion chemical ionization (NCI) mode with single-ion monitoring (SIM) and with a fixed-filament emission current and electron energy of 50 mA and 150 eV, respectively. Methane was used as the reagent gas for the NCI operation and the pressure was set to 0.18 mTorr.
Enzyme Kinetic Analysis
The microsomal VPA metabolism assay was performed as described above, at substrate concentrations ranging from 0.25 to 50 mM. The apparent Km and Vmax values were determined by nonlinear regression of the substrate concentration-metabolite formation data using the MichaelisMenten model (Enzyme Kinetics Modulet, Version 1.1, SPSS Inc., Chicago, IL, USA).
Statistics
Data were analyzed by one-way analysis of variance (SigmaStatt, version 1.0, Jandel Scientific Co., San Rafael, CA, USA). In cases where it was appropriate, they were assessed by the Student Newman-Keuls test. The level of significance was set a priori at Po0.05.
